RI

RIBOMIC Inc.

Develops RNA aptamer therapeutics for ophthalmology, pain, fibrosis, and other unmet medical needs.

4591 | T

Overview

Corporate Details

ISIN(s):
JP3974850004
LEI:
Country:
Japan
Address:
港区白金台3−16−13 白金台ウスイビル6階
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

RIBOMIC Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of aptamer therapeutics. The company utilizes its proprietary RiboART system, a unique platform technology, to generate first-in-class, molecularly targeted drugs using RNA aptamers. RIBOMIC's research and development pipeline focuses on addressing unmet medical needs in a range of therapeutic areas, including ophthalmic disorders, pain, fibrosis, bone diseases, and rare diseases. The company pursues its mission through internal drug development programs and strategic partnerships within the pharmaceutical industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 08:30
Registration Form
確認書
Japanese 8.0 KB
2025-11-12 08:30
Interim Report
半期報告書-第23期(2025/04/01-2026/03/31)
Japanese 261.6 KB
2025-07-23 08:45
Registration Form
有価証券届出書(組込方式)
Japanese 326.2 KB
2025-06-20 03:50
Registration Form
確認書
Japanese 7.9 KB
2025-06-20 03:49
Governance Information
内部統制報告書-第22期(2024/04/01-2025/03/31)
Japanese 22.3 KB
2025-06-20 03:43
Annual Report
有価証券報告書-第22期(2024/04/01-2025/03/31)
Japanese 2.0 MB
2024-11-13 02:14
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-11-13 02:13
Interim Report
半期報告書-第22期(2024/04/01-2025/03/31)
Japanese 207.6 KB
2024-06-26 04:47
Post-Annual General Meeting Information
臨時報告書
Japanese 22.7 KB
2024-06-26 04:45
Governance Information
内部統制報告書-第21期(2023/04/01-2024/03/31)
Japanese 22.1 KB
2024-06-26 04:44
Registration Form
確認書
Japanese 8.0 KB
2024-06-26 04:43
Annual Report
有価証券報告書-第21期(2023/04/01-2024/03/31)
Japanese 2.0 MB
2024-02-14 02:26
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-02-14 02:25
Quarterly Report
四半期報告書-第21期第3四半期(2023/10/01-2023/12/31)
Japanese 178.6 KB
2023-11-13 08:01
Report Publication Announcement
確認書
Japanese 7.9 KB

Automate Your Workflow. Get a real-time feed of all RIBOMIC Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for RIBOMIC Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for RIBOMIC Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AngioLab, Inc. Logo
Develops anti-angiogenic therapeutics and foods for angiogenesis-related diseases.
South Korea
251280
Anixa Biosciences Inc Logo
Clinical-stage biotech developing CAR-T immunotherapies and vaccines to fight cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
Developing oral therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.
United States of America
ANVS
Aoyama Zaisan Networks Company,Limited Logo
Consulting on inheritance and business succession for individuals and corporations.
Japan
8929
APG SGA SA Logo
Switzerland's leading OOH media firm offering digital and analogue outdoor advertising solutions.
Switzerland
APGN.SW
Biotech R&D using a miniature pig model, offering CRO services and biomaterials to pharma.
South Korea
149300
ARM HOLDINGS PLC /UK Logo
Licenses energy-efficient CPU IP for AI, mobile, automotive, IoT, and cloud markets.
United States of America
ARM
Arterra Bioscience Logo
Develops natural active ingredients via biotechnology for cosmetic, pharma, and food sectors.
Italy
ABS
ARVINAS, INC. Logo
Develops protein degradation drugs for oncology & neuroscience, targeting undruggable proteins.
United States of America
ARVN
ASUA Inc. Logo
Consulting and solutions provider enhancing logistics safety and efficiency with IoT and telecom.
Japan
246A

Talk to a Data Expert

Have a question? We'll get back to you promptly.